Literature DB >> 1281659

HIV-1 intrapatient sequence diversity in the immunogenic V3 region.

B Korber1, S Wolinsky, B Haynes, K Kunstman, R Levy, M Furtado, P Otto, G Myers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1281659     DOI： 10.1089/aid.1992.8.1461

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  12 in total

1.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

2.  Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline.

Authors:  R B Markham; W C Wang; A E Weisstein; Z Wang; A Munoz; A Templeton; J Margolick; D Vlahov; T Quinn; H Farzadegan; X F Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

3.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

4.  Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis.

Authors:  B T Korber; R M Farber; D H Wolpert; A S Lapedes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

5.  Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.

Authors:  E J Park; G V Quinnan
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.

Authors:  P F Zhang; X Chen; D W Fu; J B Margolick; G V Quinnan
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

Authors:  R I Connor; B T Korber; B S Graham; B H Hahn; D D Ho; B D Walker; A U Neumann; S H Vermund; J Mestecky; S Jackson; E Fenamore; Y Cao; F Gao; S Kalams; K J Kunstman; D McDonald; N McWilliams; A Trkola; J P Moore; S M Wolinsky
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease.

Authors:  S Ganeshan; R E Dickover; B T Korber; Y J Bryson; S M Wolinsky
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 strains in the lungs of infected individuals evolve independently from those in peripheral blood and are highly conserved in the C-terminal region of the envelope V3 loop.

Authors:  S Itescu; P F Simonelli; R J Winchester; H S Ginsberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

10.  Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences.

Authors:  B T Korber; K J Kunstman; B K Patterson; M Furtado; M M McEvilly; R Levy; S M Wolinsky
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.